Optimising the management of asthma using FeNO to direct the use of inhaled steroids: the OPTIMAN study. A real-life implementation of biomarker (FeNO) based diagnosis and management of asthma in primary care

niversity of Oxford0 个研究点目标入组 254 人开始时间: 2019年11月14日最近更新: 2024年2月19日

适应症

试验速览

暂无简介。

•1. Participant is willing and able to give informed consent for participation in the study
•2. Male or female, aged 18 years or above
•3. Either (i) newly presenting with a possible diagnosis of asthma or (ii) having been previously diagnosed with asthma
•and taking high dose inhaled corticosteroids
•4. Able to use the NiOX FeNO monitoring equipment

•1. Cannot give informed consent
•2. Unable to obtain a satisfactory FeNO level recording
•3. Severe life-threatening condition or one that would be anticipated to lead to death or disability within 1 year of study period
•4. Current history of primary lung malignancy or current active pulmonary TB
•5. Clinically relevant disease or disorder (past or present) which in the opinion of the investigator may either put the subject at risk because of participating in the study or may influence the results of the study or the subject's ability to participate in the study

发起方